Focus Partners Advisor Solutions LLC Decreases Stake in Thermo Fisher Scientific Inc. $TMO

Focus Partners Advisor Solutions LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 55.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,259 shares of the medical research company’s stock after selling 2,828 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Thermo Fisher Scientific were worth $917,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Keeler Thomas Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $786,000. Leelyn Smith LLC lifted its position in shares of Thermo Fisher Scientific by 7.9% during the 2nd quarter. Leelyn Smith LLC now owns 8,206 shares of the medical research company’s stock worth $3,327,000 after buying an additional 601 shares during the last quarter. CNB Bank lifted its position in shares of Thermo Fisher Scientific by 13.3% during the 2nd quarter. CNB Bank now owns 2,112 shares of the medical research company’s stock worth $856,000 after buying an additional 248 shares during the last quarter. PKO Investment Management Joint Stock Co lifted its position in shares of Thermo Fisher Scientific by 25.0% during the 2nd quarter. PKO Investment Management Joint Stock Co now owns 7,500 shares of the medical research company’s stock worth $3,041,000 after buying an additional 1,500 shares during the last quarter. Finally, Sage Mountain Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 6.3% during the 2nd quarter. Sage Mountain Advisors LLC now owns 2,580 shares of the medical research company’s stock worth $1,046,000 after buying an additional 153 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on TMO shares. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. UBS Group upped their price target on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research report on Thursday, October 23rd. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target for the company in a research report on Friday, July 11th. Finally, Barclays upped their price target on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Nineteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $594.65.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 17,104 shares of the company’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at $65,247,057.48. This represents a 13.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, October 24th. The stock was sold at an average price of $574.15, for a total transaction of $229,660.00. Following the transaction, the executive vice president directly owned 21,152 shares in the company, valued at approximately $12,144,420.80. This trade represents a 1.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 54,420 shares of company stock valued at $28,134,684 in the last ninety days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Down 1.0%

Shares of Thermo Fisher Scientific stock opened at $558.18 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The company has a market cap of $210.77 billion, a P/E ratio of 32.25, a PEG ratio of 3.30 and a beta of 0.77. The firm has a fifty day moving average of $506.77 and a two-hundred day moving average of $455.26.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same period in the prior year, the company posted $5.28 EPS. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.